Abstract
The leukaemias are a heterogeneous group of blood cancers, which together, caused 310,000 deaths in 2016. Despite significant research into their biology and therapeutics, leukaemia is predicted to account for an increased 470,000 deaths in 2040. Many subtypes remain without targeted therapy, and therefore the mainstay of treatment remains generic cytotoxic drugs with bone marrow transplant the sole definitive option. In this review, we will focus on cellular mechanisms which have the potential for therapeutic exploitation to specifically target and treat this devastating disease. We will bring together the disciplines of autophagy and extracellular vesicles, exploring how the dysregulation of these mechanisms can lead to changes in the leukaemic microenvironment and the subsequent propagation of disease. The dual effect of these mechanisms in the disease microenvironment is not limited to leukaemia; therefore, we briefly explore their role in autoimmunity, inflammation and degenerative disease.
| Original language | English |
|---|---|
| Pages (from-to) | 501 - 512 |
| Number of pages | 12 |
| Journal | Current Cancer Drug Targets |
| Volume | 20 |
| Issue number | 7 |
| Early online date | 28 Apr 2020 |
| DOIs | |
| Publication status | Published - 2020 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Autoimmunity
- Autophagy
- Extracellular vesicles
- Leukaemia
- Therapeutic
- Tumour microenvironment
Profiles
-
Stuart Rushworth
- Norwich Medical School - Professor
- Metabolic Health - Director
- Cancer Studies - Member
Person: Research Group Member, Academic, Teaching and Research
-
Tom Wileman
- Norwich Medical School - Emeritus Professor
- Metabolic Health - Member
- Gastroenterology and Gut Biology - Member
Person: Honorary, Research Group Member
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver